Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in Iba1 level at 3 mg/kg per day, ip administrated for 1 week by Western blotting analysis
Assay data:2 Active, 2 Tested
SummaryCompounds, ActivePubMed Citation
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in Iba1 level in hippocampus at 1.5 mg/kg, ip pretreated with amyloid beta for 1 week followed by twice daily compound administration for 1 week and measured on day 14 by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in GFAP expression at 3 mg/kg per day, ip administrated for 1 week by Western blotting analysis
Assay data:2 Tested
SummaryPubMed Citation
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in GFAP expression in hippocampus at 1.5 mg/kg, ip pretreated with amyloid beta for 1 week followed by twice daily compound administration for 1 week and measured on day 14 by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as reversal of SYN levels at 3 mg/kg per day, ip administrated for 1 week by Western blotting analysis
Assay data:1 Active, 1 Tested
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as reversal of PSD-95 levels at 3 mg/kg per day, ip administrated for 1 week by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as recovery of p35 protein levels in hippocampus at 3 mg/kg per day, ip administrated for 1 week by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in p25/p35 ratio in hippocampus at 3 mg/kg per day, ip administrated for 1 week by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in p25 protein levels in hippocampus at 3 mg/kg per day, ip administrated for 1 week by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in Cdk5 overexpression in hippocampus at 3 mg/kg per day, ip administrated for 1 week by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in p25 protein levels in hippocampus at 1.5 mg/kg, ip pretreated with amyloid beta for 1 week followed by twice daily compound administration for 1 week and measured on day 14 by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in Cdk5 overexpression in hippocampus at 1.5 mg/kg, ip pretreated with amyloid beta for 1 week followed by twice daily compound administration for 1 week and measured on day 14 by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in pro-caspase-3 expression in hippocampus at 3 mg/kg per day, ip administrated for 1 week by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in caspase-3 expression in hippocampus at 3 mg/kg per day, ip administrated for 1 week by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in pro-caspase-3 expression in hippocampus at 1.5 mg/kg, ip pretreated with amyloid beta for 1 week followed by twice daily compound administration for 1 week and measured on day 14 by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as decrease in caspase-3 expression in hippocampus at 1.5 mg/kg, ip pretreated with amyloid beta for 1 week followed by twice daily compound administration for 1 week and measured on day 14 by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as reversal of SYN levels in hippocampus at 1.5 mg/kg, ip pretreated with amyloid beta for 1 week followed by twice daily compound administration for 1 week and measured on day 14 by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as reversal of PSD-95 levels in hippocampus at 1.5 mg/kg, ip pretreated with amyloid beta for 1 week followed by twice daily compound administration for 1 week and measured on day 14 by Western blotting analysis
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as reversal of memory deficits at 3 mg/kg per day, ip administrated for 1 week by T-Maze test
Assay data:1 Active, 2 Tested
Antialzheimer activity against oligomeric amyloid beta (25 to 35) induced Sprague-Dawley rat model assessed as reversal of memory deficits at 1.5 mg/kg, ip pretreated with amyloid beta for 1 week followed by twice daily compound administration for 1 week and measured on day 14 by T-Maze test
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on